SCHEMBL17426420

SCHEMBL17426420

c1ccc(N(c2ccccc2)c2ccc(-n3c4ccccc4c4c5oc6c(ccc7c6c6ccccc6n7-c6ccccc6)c5ccc43)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 3/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40
BRCA1 P38398 1/20 0.40
MAPK8 P45983 2/20 0.33
JAK2 O60674 1/20 0.32
JAK3 P52333 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
MAPT P10636 2/20 0.31
CYP2D6 P10635 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17426435 0.99 KDM4E (0.42) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426261 0.96 L3MBTL1 (0.41) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426258 0.95 L3MBTL1 (0.41) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426396 0.94 L3MBTL1 (0.38) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426278 0.94 L3MBTL1 (0.38) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426312 0.94 KDM4E (0.41) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426393 0.94 L3MBTL1 (0.38) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426265 0.94 L3MBTL1 (0.38) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL17426264 0.94 L3MBTL1 (0.38) KDM4EL3MBTL1ATMALDH1A1KMT2A
SCHEMBL19695718 0.92 L3MBTL1 (0.41) KDM4EL3MBTL1ATMALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9842996-B2 Amine compound having hetero-fused ring and organic electroluminescent element using amine compound IDEMITSU KOSAN CO., LTD. (JP) 2017-12-12 US disclosed
US-9842996-B2 Amine compound having hetero-fused ring and organic electroluminescent element using amine compound IDEMITSU KOSAN CO., LTD. (JP) 2017-12-12 US disclosed
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2016-01-14 US disclosed
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND CTCF, SAT1, TEAD2 KDM4E 942/4885L3MBTL1 2674/4885ATM 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.